Filing Flows › Bionano Genomics (BNGO) › Q2 2026 › vs Q2 2025
Bionano Genomics (BNGO) Q2 2026 vs Q2 2025 (year over year)
Bionano Genomics's revenue rose $1.4M (+21%) from $6.7M in Q2 2025 to $8.2M in Q2 2026. The biggest changes: Product +$1.4M (+22%); Product and Service Other +$55K (+13%).
Bionano Genomics, Q2 2026: revenue $8.2M (+21% year over year), operating margin -88.3%, net loss $7.4M, operating cash flow −$4.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Consumable Revenue | $4.3M | $3.3M | $1.0M | +31% |
| Instrument Revenue | $2.0M | $1.4M | $638K | +46% |
| Software Revenue | $1.4M | $1.6M | −$264K | -16% |
| Product | $7.7M | $6.3M | $1.4M | +22% |
| Product and Service Other | $478K | $423K | $55K | +13% |
| Revenue | $8.2M | $6.7M | $1.4M | +21% |
| Net loss | $7.4M | $6.9M | $566K | +8% |
| Costs & expenses | $15.6M | $14.5M | $1.1M | +7% |
| Operating costs | $15.4M | $14.5M | $856K | +6% |
| Interest & other, net | $198K | −$953K | $1.2M | — |
| Income tax | $7K | $10K | −$3K | -30% |
| Cost of revenue | $3.9M | $3.3M | $601K | +18% |
| Research & development | $3.0M | $2.9M | $57K | +2% |
| SG&A | $8.5M | $8.3M | $198K | +2% |
| Operating cash sources | $7.9M | $6.9M | $989K | +14% |
| Depreciation & amortization | $2.3M | $2.4M | −$84K | -4% |
| Share-based compensation | $970K | $1.1M | −$110K | -10% |
| Cash used in operations | $4.7M | $3.5M | $1.2M | +34% |
| Net loss absorbed | $7.4M | $6.9M | $566K | +8% |
| Working capital & other | $513K | $90K | $423K | +470% |
Questions
How much did Bionano Genomics's revenue grow year over year in Q2 2026?
Bionano Genomics's revenue rose $1.4M (+21%) from $6.7M in Q2 2025 to $8.2M in Q2 2026.
What drove Bionano Genomics's revenue change in Q2 2026?
Product +$1.4M (+22%); Product and Service Other +$55K (+13%).